Observational Analysis of 2 Million Surgical Cases Links GLP-1 Use to 11% Lower Cardiovascular Complications

Researchers queried the Epic Cosmos database for adults undergoing procedures longer than 60 minutes with at least 24-hour stays from 2016-2024. Of 145,610 GLP-1 users, matched analysis showed reduced rates of myocardial infarction, stroke, cardiac injury, and death, plus fewer surgical-site, urinary, pulmonary, and bloodstream infections. Proposed mechanisms include improved glycemic control, reduced inflammation, and hemodynamic stability during surgical stress.

This pattern aligns with cardiovascular outcome trials such as SELECT and SUSTAIN-6, where semaglutide lowered major adverse cardiac events by 20% in nonsurgical populations. Perioperative data remain sparse; prior small studies reported conflicting signals on aspiration risk and delayed gastric emptying, leaving anesthesiologists without clear perioperative protocols.

The study is observational and cannot establish causality; residual confounding by healthier user behavior or better overall diabetes management is possible. Randomized perioperative trials measuring hard endpoints are required before guideline changes.

Evidence quality is moderate: large sample size and matching strengthen associations, yet selection bias and lack of randomization limit causal inference; next steps demand multicenter RCTs with standardized GLP-1 continuation protocols.